ERBB2 and breast cancer: The new insights into mechanisms that control the surface expression of overexpressed ErbB2 identified here support the potential of exploring combined treatment with Trastuzumab and ER stress-inducing agents in ErbB2-overexpressing breast cancers with loss of CHIP expression.